Healthcare
Latest Healthcare Analysis
View More![semaglutide weight loss injection pens prescription or otc medicine concept.](https://files.valuethemarkets.com/containers/assets/weight-loss-injections.jpg/d09e6248cd45a93ccc7d76e8180e01b2.jpg)
Viking Therapeutics Accelerates Weight Loss Drug Development
Viking Therapeutics' fast-tracked weight loss injection could reshape the market, impacting investors' portfolios and strategies.
![products, manufacturing facility, and global reach of Embecta.](https://files.valuethemarkets.com/containers/assets/embecta-potential-sale-1721644228.jpg/d60be3395c028ed17ae5d3963b82d137.jpg)
Embecta Considers Sale Amid Struggles
Embecta Corp, the top insulin pen needle producer, eyes a sale after a 70% share price drop post-spin-off.
![Doctor checking disabled person pateint leg at hospital, Muscle weakness.](https://files.valuethemarkets.com/containers/assets/muscular-dystrophy.jpeg/be8483d5f755ab1813503745ce7b31d7.jpeg)
SRPT Stock: Sarepta's Elevidys Gets Green Light for Duchenne Patients
Sarepta Therapeutics Inc (NASDAQ: SRPT) achieves FDA approval for its gene therapy for Duchenne muscular dystrophy in patients aged four and older.
![a modern laboratory setting with scientists working on drug discovery.](https://files.valuethemarkets.com/containers/assets/canaquest-bolsters-team-for-cq-001-trials.jpg/a025f82970df1ba81420752352d552d6.jpg)
CanaQuest Bolsters Team for CQ-001 Trials
CanaQuest Medical (OTC: CANQF) adds experts to advance CQ-001 through clinical trials for FDA approval in epilepsy.
Top Picks
View More![](https://files.valuethemarkets.com/containers/assets/Growth-Stocks.jpg/a79ba4cc128035f5fd5f6cc645d7f342.jpg)
Top Growth Stocks Q2 2022
Growth investing tends to be a medium to long-term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
![growth-stocks-for-q1-2022.](https://files.valuethemarkets.com/containers/assets/Top-Picks_Growth-Stocks.jpg/75fdfb31759189a6c811432126a663ca.jpg)
Top Growth Stocks Q1 2022
Growth investing tends to be a medium to long term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
![momentum-stocks-for-q1-2022.](https://files.valuethemarkets.com/containers/assets/Top-Picks_Momentum-Stocks.jpg/74ec59f41c3e54d1808d6c1c1d210b6d.jpg)
Top Momentum Stocks Q1 2022
Momentum investing tends to be a short-term investing strategy. Investors looking to buy shares in a stock look for signs of upward momentum and...
![](https://files.valuethemarkets.com/containers/assets/Top-Picks-_-Healthcare-2.jpg/d45a63245b033c9d7769cf89ada14b0c.jpg)
Q4 2021 Top Healthcare stocks to consider
Healthcare can be a lucrative investment area, but it's also a challenging sector to invest in. Here are some top health stocks in momentum, growth...
Press Releases
View MoreCardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research...
![](https://files.valuethemarkets.com/containers/assets/i6gq3lh68x4frq5hun5deoezbkx1retghyoawlrn8i6ff0phb-out-0.png/89a3c8d8be61c497b31ba1b64ccfe18f.png)
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, ON – November 1, 2023 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...